The association between triglycerides and incident cardiovascular disease: What is “optimal”?
Tsion Aberra(Clinical Research Institute), Ann Marie Návar(Clinical Research Institute), Eric D. Peterson(Duke University), Neha J. Pagidipati(Alnylam Pharmaceuticals (United States)), Craig Granowitz(Inserm), Sephy Philip(Amarin (United States)), Daniel Wojdyla, Hillary Mulder(Clinical Research Institute)
Cited by 119
Related Papers
WHO analysis of causes of maternal death: a systematic review
|The Lancet|2006|4k
An Updated Definition of Stroke for the 21st Century
|Stroke|2013|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k